Sign In
Buy APVO
$4.11
-0.0200 (-0.484%)
At Close: Jul 31, 2026
Together with cash on hand, the fully leveraged facility extends Aptevo's funding runway into 2029, enabling achievement of key clinical and preclinical milestones SEATTLE, WA / ACCESS Newswire / Janu
What's Going On With Aptevo Therapeutics Stock Today?
10:24am, Friday, 26'th Dec 2025
Shares of Aptevo Therapeutics Inc. (NASDAQ: APVO) are trading lower Friday after the Seattle-based company announced a one-for-eighteen reverse stock split.
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split
08:05am, Friday, 26'th Dec 2025
SEATTLE, WA / ACCESS Newswire / December 26, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its
Critical Contrast: Aptevo Therapeutics (NASDAQ:APVO) vs. Neumora Therapeutics (NASDAQ:NMRA)
03:30am, Saturday, 20'th Dec 2025
Neumora Therapeutics (NASDAQ: NMRA - Get Free Report) and Aptevo Therapeutics (NASDAQ: APVO - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast t
Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025
08:05am, Tuesday, 09'th Dec 2025
100% of patients in Cohorts 1-3 remain free of cytokine release syndrome CRIS-7-derived CD3 design underpins a controlled T-cell response, supporting the differentiated safety profile, combinability w
Aptevo Therapeutics (APVO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
10:57am, Wednesday, 19'th Nov 2025
Aptevo Therapeutics (APVO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement
First data on Aptevo's new molecule presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting SEATTLE, WASHINGTON / ACCESS Newswire / November 10, 2025 / Aptevo Therapeutics ("Aptevo"
Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update
08:05am, Thursday, 06'th Nov 2025
89% of evaluable mipletamig patients achieve remission in combination therapy for frontline AML across two trials Introduces first trispecific molecules, APVO451 and APVO452, advancing therapies desig
SEATTLE, WASHINGTON / ACCESS Newswire / October 8, 2025 / Aptevo Therapeutics ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company developing novel bispecific and trispeci
Aptevo Therapeutics shares spike on promising trial results for leukemia therapy
12:21pm, Tuesday, 16'th Sep 2025
Aptevo Therapeutics (NASDAQ:APVO) saw its shares jump sharply after the company reported encouraging clinical data from its Phase 1b/2 RAINIER trial evaluating mipletamig, a first-in-class CD123 x CD3
Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML
08:30am, Tuesday, 16'th Sep 2025
No dose-limiting toxicities or cytokine release syndrome observed in RAINIER to date; mipletamig shows consistently favorable safety and tolerability Trial progressing efficiently, Cohort 4 open for e
Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules
08:45am, Thursday, 04'th Sep 2025
New candidates, APVO452 and APVO451, harness proprietary ADAPTIR-FLEXTM design to target prostate and multiple solid tumor cancers by simultaneously engaging tumor antigens, T cells, and immunosuppres
Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer
08:05am, Wednesday, 13'th Aug 2025
Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer. Engineered for precision T-cell activation in prostate cancer; part of Aptevo's growing CRIS
Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update
08:05am, Monday, 11'th Aug 2025
Mipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio expansion with APVO455, a Nectin-4 x CD3 bispecific for multiple solid tumor types
Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules
11:30am, Friday, 20'th Jun 2025
SEATTLE, WASHINGTON / ACCESS Newswire / June 20, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on
